X0306 4 2016-11-21 0 0001048477 BIOMARIN PHARMACEUTICAL INC BMRN 0001221590 BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901 1 1 0 0 Chief Executive Officer Common Stock 2016-11-21 2016-11-21 4 M 0 69744 26.490 A 240426 D Common Stock 2016-11-21 2016-11-21 4 S 0 69744 87.5556 D 170682 D Common Stock 2016-11-22 2016-11-22 4 M 0 69743 26.490 A 240425 D Common Stock 2016-11-22 2016-11-22 4 S 0 69743 85.6934 D 170682 D Common Stock 182801 I Shares held by Jean-Jacques Bienaime Family Trust Stock Option (right to buy Common Stock) 26.49 2016-11-21 2016-11-21 4 M 0 69744 0 D 2011-11-12 2021-05-11 Common Stock 69744 210256 D Stock Option (right to buy Common Stock) 26.49 2016-11-22 2016-11-22 4 M 0 69743 0 D 2011-11-12 2021-05-11 Common Stock 69743 140513 D Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime. The amount of securities beneficially owned has been updated from the reporting person's prior Form 4 to reflect (a) changes in the form of ownership due to transfers made by the reporting person between accounts held directly and indirectly in the name of the Bienaime Family Trust and the Jean-Jacques Bienaime Family Trust and (b) an additional 4,357 shares beneficially owned by the reporting person pursuant to a reconciliation of the Company's records following the completion of the transfer of shares in connection with the reporting person's marital separation agreement. The price in column 4 is the weighted average price. The price actually received ranged from $86.74 to $89.59. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. The price in column 4 is the weighted average price. The price actually received ranged from $84.45 to $88.16. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Reflects the number of stock options outstanding after the transaction from this specific stock option grant. /s/ Laura Randall Woodhead, Attorney-in-Fact 2016-11-23